Objectives: One of the two new human papillomavirus (HPV) vaccines protects against HPV
types 6 and 11, which cause over 95% of genital warts, in addition to protecting against HPV …

Objective The quadrivalent human papillomavirus (HPV) vaccine is effective against HPV
types responsible for 90% of anogenital warts. This study estimated the quality of life lost to …

Background: The burden of anogenital warts will be a determining factor when making
decisions about the type of human papillomavirus (HPV) vaccine to be used (bivalent or …

Objectives To estimate the loss of quality of life and cost of treatment associated with genital
warts seen in sexual health clinics. Methods A cross-sectional questionnaire study and case …

Background Genital warts, which are caused by infection with human papillomavirus (HPV),
are one of the most common sexually transmitted diseases in Europe. Although genital warts …

Background: Data on the burden of genital warts in terms of treatment costs and detriment to
quality of life (QoL) are required to assess cost-effectiveness of quadrivalent human …

To assess gender-specific impact of genital warts on health-related quality of life (HRQoL),
and to explore to what extent sexual characteristics and clinical symptoms influenced the …

Background Data on the psychosocial burden of human papillomavirus (HPV)-related
diseases other than cervical cancer are scarce. The objectives of this study were to measure …

OBJECTIVE: Worldwide, genital warts, caused by human papillomavirus (HPV) is a
common, sexually transmitted disease. The overall disease management strategy for genital …

Background Information on the health-related quality of life (HRQoL) of patients with genital
warts (GW) in populations in mainland China is still limited. The aim of the study was to use …